The type of diabetes determines either blood sugar monitoring, insulin or oral medications as a treatment. Treatment for type 1 diabetes involves insulin injections or the use of an insulin pump, frequent blood sugar checks, and carbohydrate counting. Treatment of type 2 diabetes primarily involves monitoring of your blood sugar, along with diabetes medications, insulin or both. The elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications.
The global diabetes drugs and devices market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug type (insulin derivatives – short-acting, intermediate-acting, long-acting, premixed, and rapid-acting insulin; oral anti-diabetes drugs – alpha-glucosidase inhibitors, biguanides, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylureas, thiazolidinediones; and non-insulin injectable anti-diabetes drugs – GLP-1 analogs), device type (diabetes monitoring and diagnostic devices – analog glucose meter, continuous glucose monitoring devices, glucose test strips, lancets and lancing devices; insulin delivery devices – insulin injectors, pens, pumps, syringes, etc.), and forecasts growth trends (CAGR% – 2017 to 2021).
The global diabetes drugs and devices market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global diabetes drugs and devices market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global diabetes drugs and devices market and included in this report are Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Co. Ltd.